citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
Company profile
Ticker
CTXR
Exchange
Website
CEO
Myron Holubiak
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Trail One, Inc., TrailOne, Inc.
SEC CIK
Corporate docs
Subsidiaries
Citius Pharmaceuticals, LLC • Leonard-Meron Biosciences, Inc. • NoveCite, Inc. • Citius Oncology, Inc. ...
CTXR stock data
Latest filings (excl ownership)
8-K
Other Events
5 Apr 24
8-K
Other Events
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Mar 24
EFFECT
Notice of effectiveness
4 Mar 24
S-3
Shelf registration
23 Feb 24
S-8
Registration of securities for employees
23 Feb 24
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
15 Feb 24
10-Q
2024 Q1
Quarterly report
14 Feb 24
8-K
Other Events
14 Feb 24
ARS
2023 FY
Annual report to shareholders
26 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.48 mm | 26.48 mm | 26.48 mm | 26.48 mm | 26.48 mm | 26.48 mm |
Cash burn (monthly) | 2.27 mm | 1.27 mm | 3.37 mm | 3.06 mm | 2.27 mm | 2.42 mm |
Cash used (since last report) | 15.10 mm | 8.45 mm | 22.48 mm | 20.39 mm | 15.10 mm | 16.13 mm |
Cash remaining | 11.38 mm | 18.03 mm | 4.00 mm | 6.09 mm | 11.38 mm | 10.35 mm |
Runway (months of cash) | 5.0 | 14.2 | 1.2 | 2.0 | 5.0 | 4.3 |
Institutional ownership, Q3 2023
15.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 73 |
Opened positions | 9 |
Closed positions | 11 |
Increased positions | 17 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 16.77 bn |
Total shares | 24.78 mm |
Total puts | 18.00 k |
Total calls | 440.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.79 mm | $5.33 bn |
Vanguard | 6.83 mm | $4.67 bn |
Geode Capital Management | 2.68 mm | $1.83 bn |
STT State Street | 2.20 mm | $1.51 bn |
NTRS Northern Trust | 1.05 mm | $721.54 mm |
Nuveen Asset Management | 484.65 k | $331.69 mm |
Charles Schwab Investment Management | 356.99 k | $244.33 mm |
BK Bank Of New York Mellon | 342.32 k | $234.29 mm |
HighTower Advisors | 209.20 k | $143.00 mm |
Gsa Capital Partners | 198.49 k | $135.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Mazur Leonard L | Warrant to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.42 | 1,165,048 | 1.65 mm | 1,165,048 |
3 Apr 24 | Mazur Leonard L | Warrant to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 1.42 | 1,165,048 | 1.65 mm | 0 |
3 Apr 24 | Holubiak Myron Z | Warrant to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.42 | 129,450 | 183.82 k | 129,450 |
3 Apr 24 | Holubiak Myron Z | Warrant to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 1.42 | 129,450 | 183.82 k | 0 |
14 Mar 24 | Robert Joseph Smith | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 0.69 | 75,000 | 51.75 k | 75,000 |
10 Oct 23 | Webb Carol | Options to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.7 | 75,000 | 52.50 k | 75,000 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24
University Of Minnesota Masonic Cancer Center Intends To Expand Cirtrus Pharmaceuticals' Ongoing Investigator-Initiated Phase 1 Trial Of LYMPHIR In Combination With FDA-Approved CAR-T Products For B-cell Lymphomas
11 Apr 24
Citius Pharmaceuticals Announces FDA Acceptance Of BLA Resubmission of LYMPHIR For Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma
18 Mar 24
Citius Pharma Q1 EPS $(0.06) Down From $(0.02) YoY
14 Feb 24
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
14 Feb 24
Press releases
Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment
18 Apr 24
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
11 Apr 24
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
4 Apr 24
Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
22 Mar 24
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
7 Mar 24